📰 Accessed May News
Accessed May News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Accessed May. Real-time updates on events, politics, business and more.
June 13, 2024
Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Augtyrotm (repotrectinib) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that...
June 12, 2024
At a symposium on the impact of the Inflation Reduction Act (IRA) on pharmaceutical innovation and access, speakers urged the audience to join in advocating for changes to the law.
June 4, 2024
/PRNewswire/ -- Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, announced the outcome of the U.S. Food and Drug...
June 4, 2024
This essay examines a deep underlying cause of many societal ills in the Pacific: trauma resulting from abuse. Abuse, combined with patriarchal, colonial and capitalistic influences lead to depression, gender-based violence, addictions, and broken relationships, but we don't usually talk about trauma. Any viable way forward must embrace inclusion, creation of safe spaces to talk…
June 2, 2024
The proof-of-concept study showed that antisense oligonucleotides developed by the researchers successfully restored cellular development and brain cell function in patients with the disease characterized by multiorgan dysfunction.
June 1, 2024
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS) of 17.5 months in patients with previously treated PD-L1-positive
June 1, 2024
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive
May 31, 2024
This article from the Lung Ambition Alliance discusses how they are tackling challenges and harnessinginnovation to optimize lung cancer outcomes for patients.